Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Regular insulin, which is often used in pregnancy for the treatment of diabetes, has some drawbacks: it starts its action from 30 to 60 min after subcutaneous injection and it peaks too late (2-3 ...

Insulin pump market growth is propelled by advancements in technology, rising global diabetes prevalence, and increased demand for precision diabetes management.New Delhi, Feb. 06, 2025 (GLOBE ...

Transdermal delivery of insulin is not new ... studies – delivers longer-lasting and more stable levels than subcutaneous injections, without breaking the skin layers. The prototype transdermal ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery system that could save lives.

CIRM awards US$ 4 mn grant to Entos Pharma to advance development of ENTLEP001, a durable and redosable genetic medicine to treat CGL: San Diego Friday, February 7, 2025, 15:00 Hr ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...